Summary

Current management of gout is suboptimal, and patients often do not achieve serum uric acid (SUA) targets with allopurinol monotherapy. This article discusses the results of 2 replicate phase 3 studies known as Combining Lesinurad With Allopurinol in Inadequate Responders [CLEAR 1 and CLEAR 2; NCT01510158 and NCT01493531, respectively] conducted in symptomatic adults with gout.